A Phase 2A Trial of DT402 for Autism Spectrum Disorder

Recruiting now · Phase 2

Conditions studied: Autism Spectrum Disorder, ASD

In brief

A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder

Key facts

Study ID

NCT07303907

Run by

Definium Therapeutics US, Inc.

People needed

20

Starts

2025-12-03

Expected to finish

2027-08-01

Last updated by the study team

2026-04-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)
• Male or Female aged 18 to 65
• Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66

You may not qualify if…

• Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking
• First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
• Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
• Any clinically significant unstable illness

Where it is running

• Spectrum Neuroscience and Treatment Institute — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.